Covered recipient · General Payments record
ADDI ZNAMENSKY
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2021–2025
$1,368.28
- Reported across 60 records
- CMS publication 2026-06-30
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2025 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $403.28 | 18 |
By paying entity
PY2025 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $193.97 | 7 |
| Exact Sciences Corporation | $43.39 | 2 |
| Novo Nordisk AS | $39.14 | 2 |
| Lilly USA, LLC | $37.07 | 2 |
| Acerta Pharma LLC | $34.76 | 2 |
| Axsome Therapeutics, Inc. | $18.55 | 1 |
| Amgen Inc. | $18.24 | 1 |
| PFIZER INC. | $18.16 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2025 (18)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $18.34 | 03/24/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1204867793 | CMS |
| ABBVIE INC. | $4.96 | 05/01/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1204867797 | CMS |
| ABBVIE INC. | $15.32 | 06/02/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1204867800 | CMS |
| ABBVIE INC. | $17.95 | 08/14/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1204867804 | CMS |
| ABBVIE INC. | $122.79 | 08/20/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1204867808 | CMS |
| ABBVIE INC. | $9.68 | 09/02/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1204867811 | CMS |
| ABBVIE INC. | $4.93 | 09/02/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1204867816 | CMS |
| Amgen Inc. | $18.24 | 06/12/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1228521786 | CMS |
| AstraZeneca Pharmaceuticals LP | $19.00 | 06/05/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1207184411 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.76 | 09/10/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1206910758 | CMS |
| Axsome Therapeutics, Inc. | $18.55 | 10/03/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1235567681 | CMS |
| Exact Sciences Corporation | $26.04 | 03/06/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1235539845 | CMS |
| Exact Sciences Corporation | $17.35 | 08/13/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1235539850 | CMS |
| Lilly USA, LLC | $18.05 | 03/11/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1186491425 | CMS |
| Lilly USA, LLC | $19.02 | 09/18/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1186488981 | CMS |
| Novo Nordisk Inc | $20.43 | 04/02/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1188885866 | CMS |
| Novo Nordisk Inc | $18.71 | 05/14/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1188444030 | CMS |
| PFIZER INC. | $18.16 | 08/19/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1230593779 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2021, 2022, 2023, 2024, 2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.